title: Should pediatric patients with hyperlipidemia receive drug therapy?
abstract: Hyperlipidemia is now established as a major risk factor for causation of coronary heart disease (CHD) in adults; however, there is much debate on the level of coronary risk at which lipid-lowering drugs should be used. These issues of possible harm or lack of benefit from long-term use of lipid-lowering therapy, and cost effectiveness, are also pertinent in the pediatric setting. Evidence from several countries indicates that children have an increasing prevalence of obesity, hyperlipidemia and type 2 diabetes mellitus. Children who have high serum lipids 'track' these increased levels into adulthood. In some countries there is a trend to screen children for hypercholesterolemia. Family history itself is a poor discriminator in determining which children need to be screened and treated. Estimation of apolipoprotein B and/or apolipoprotein E genotype can improve prediction. Measuring high density lipoprotein cholesterol also helps, but obesity appears to be the best marker for screening children at high risk. These considerations should not cloud the need for case finding and treatment of children with genetic disorders. Low fat diets have been shown to be well tolerated and effective in children; however, there are no major long-term studies demonstrating harm or benefit in those on lipid-lowering drugs. Nevertheless, concerns regarding the psychological effect and the theoretical metabolic effects of long-term lipid lowering remain. Lipid-lowering drugs should be generally restricted to children with genetic disorders of lipid metabolism. Children with diabetes mellitus, hypertension or nonlipid-related inherited disorders leading to premature CHD in adults should be treated with diet, and with lipid-lowering drugs when they reach adulthood. Children with secondary hyperlipidemia should be assessed individually. A number of drugs and nutriceuticals are available for use in children, but only a few drugs are licensed for use in children.
authors.affiliation: The Royal Oldham Hospital, Oldham, and Manchester Royal Infirmary, Manchester, United Kingdom. D.Bhatnagar@man.ac.uk
authors.forename: Deepak
authors.initials: D
authors.lastname: Bhatnagar
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002648:Child; D002792:Cholestyramine Resin / Q000627:therapeutic use; D003327:Coronary Disease / Q000517:prevention & control; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000151:congenital / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009525:Niacin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011620:Psyllium / Q000627:therapeutic use; D018570:Risk Assessment
chemical_list: D000924:Anticholesteremic Agents; D015525:Fatty Acids, Omega-3; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002792:Cholestyramine Resin; D009525:Niacin; D011620:Psyllium